Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia

Trial details

Who runs it

Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz

Trial code

NCT04466007

Record updated

27 April 2025

Original description

Phase II national, multicenter, double-blind, randomized, placebo-controlled, phase-3 clinical trial of 3 parallel groups.Read full original descriptionShow less

Multicenter, Randomized, Dose-search, Parallel, Double-blind, and Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Intramuscular Administration of Allogeneic Adipose Tissue Adult Mesenchymal Stem Cells in Diabetic Patients With Critical Limb Ischemia Without Possibility of Revascularization

Phase II national, multicenter, double-blind, randomized, placebo-controlled, phase-3 clinical trial of 3 parallel groups.

Inclusion: Patients must meet ALL of the following criteria to be included in the study:; Patients of both sexes; Age between 40 and 90 years; Severe grade vascular arteriosclerosis (category RB 4 and 5 mono or bilateral); Impossibility of surgical or endovascular revascularization or failure in revascularization surgery performed, at least 30 days before inclusion in the study, defining failure as direct non-arrival of vessels to the plantar arch; Normal biochemical parameters defined by:; Leukocytes> 3000 / mm3; Neutrophils> 1500 / mm3; Platelets> 100,000 / mm3; AST / ALT <2.5x upper limit of normal; In patients with an ischemic ulcer, it must be stable for at least 1 week; Patients under conventional medical treatment for CLI; Women of childbearing age must obtain a negative result in a urine pregnancy test performed at the time of inclusion in the study and commit to using an effective contraceptive method during their participation in the study; Patients who have not participated in any other clinical trial during the 3 months prior to the inclusion visit; Patients who sign the informed consent.

Exclusion: Previous major amputation in the target member; Patients with a previous diagnosis of ventricular arrhythmias or unstable angina; Patients diagnosed with deep vein thrombosis in the 3 months prior to their inclusion in the study; Concomitant therapy that includes hyperbaric oxygen, angiogenic agents or Cox II inhibitors; Patients previously treated with cell therapy, gene therapy or growth factors in the last year; Concomitant disease that limits life expectancy to 1 year or that does not ensure the follow-up period; Patients who have suffered a stroke or myocardial infarction in the 3 months prior to the inclusion visit; Patients with a previous diagnosis of chronic alcoholism; Uncontrolled hypertension (defined as PAS> 180 or PAD> 110 in at least 2 determinations during the selection period); Patients with severe heart failure or ejection fraction less than 30%; Severe anemia (hemoglobin <7.9g / dl) in the inclusion analysis; Patients who present SOME of the following criteria may not be selected to participate in this study:; CLI with tissue loss in the target member (category 6 of RB); Patients with septicemia; Contraindication to perfusion NMR; Proliferative retinopathy without treatment; Diabetic nephropathy in hemodialysis; Any clinically significant anomaly detected in the Selection Period and which, in the opinion of the investigator, constitutes an impediment to the correct participation of the patient in the study or the fulfillment of the procedures established therein.

ClinicalTrials.gov NCT04466007